References
- Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics. CA Cancer J Clin 2014; 64:9-29; PMID:24399786; https://doi.org/10.3322/caac.21208
- Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer 2014; 14:535-46; PMID:25056707; https://doi.org/10.1038/nrc3775
- Rosell R, Bivona TG, Karachaliou N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet 2013; 382:720-31; PMID:23972815; https://doi.org/10.1016/S0140-6736(13)61715-8
- Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-70; PMID:21436444; https://doi.org/10.1126/science.1203486
- Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015; 348:56-61; PMID:25838373; https://doi.org/10.1126/science.aaa8172
- Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015; 348:69-74; PMID:25838375; https://doi.org/10.1126/science.aaa4971
- Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004; 4:11-22; PMID:14708024; https://doi.org/10.1038/nrc1252
- Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454:436-44; PMID:18650914; https://doi.org/10.1038/nature07205
- Lee S, Margolin K. Cytokines in cancer immunotherapy. Cancers (Basel) 2011; 3:3856-93; PMID:24213115; https://doi.org/10.3390/cancers3043856
- Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Pillars article: two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999; 401:708-712. J Immunol 2014; 192:840-4; PMID:10537110; https://doi.org/10.1038/44385
- Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 2015; 15:486-99; PMID:26205583; https://doi.org/10.1038/nri3862
- Dinarello CA. Overview of the interleukin-1 family of ligands and receptors. Semin Immunol 2013; 25:389-93; PMID:24275600; https://doi.org/10.1016/j.smim.2013.10.001
- Novick D, Kim S, Kaplanski G, Dinarello CA. Interleukin-18, more than a Th1 cytokine. Semin Immunol 2013; 25:439-48; PMID:24275602; https://doi.org/10.1016/j.smim.2013.10.014
- Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev 2001; 12:53-72; PMID:11312119; https://doi.org/10.1016/S1359-6101(00)00015-0
- Lalor SJ, Dungan LS, Sutton CE, Basdeo SA, Fletcher JM, Mills KH. Caspase-1-processed cytokines IL-1beta and IL-18 promote IL-17 production by gammadelta and CD4 T cells that mediate autoimmunity. J Immunol 2011; 186:5738-48; PMID:21471445; https://doi.org/10.4049/jimmunol.1003597
- Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity 2013; 39:1003-18; PMID:24332029; https://doi.org/10.1016/j.immuni.2013.11.010
- Terme M, Ullrich E, Aymeric L, Meinhardt K, Desbois M, Delahaye N, Viaud S, Ryffel B, Yagita H, Kaplanski G et al. IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res 2011; 71:5393-9; PMID:21724589; https://doi.org/10.1158/0008-5472.CAN-11-0993
- Fabbi M, Carbotti G, Ferrini S. Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP. J Leukoc Biol 2015; 97:665-75; PMID:25548255; https://doi.org/10.1189/jlb.5RU0714-360RR
- Lebel-Binay S, Thiounn N, De Pinieux G, Vieillefond A, Debre B, Bonnefoy JY, Fridman WH, Pagès F. IL-18 is produced by prostate cancer cells and secreted in response to interferons. Int J Cancer 2003; 106:827-35; PMID:12918059; https://doi.org/10.1002/ijc.11285
- Pages F, Berger A, Henglein B, Piqueras B, Danel C, Zinzindohoue F, Thiounn N, Cugnenc PH, Fridman WH. Modulation of interleukin-18 expression in human colon carcinoma: consequences for tumor immune surveillance. Int J Cancer 1999; 84:326-30; PMID:10371355; https://doi.org/10.1002/(SICI)1097-0215(19990621)84:3%3c326::AID-IJC22%3e3.0.CO;2-K 10.1002/(SICI)1097-0215(19990621)84:3%3c326::AID-IJC22%3e3.3.CO;2-B
- Dinarello CA, Novick D, Kim S, Kaplanski G. Interleukin-18 and IL-18 binding protein. Front Immunol 2013; 4:289; PMID:24115947; https://doi.org/10.3389/fimmu.2013.00289
- Yang J, Zhu H, Murphy TL, Ouyang W, Murphy KM. IL-18-stimulated GADD45 beta required in cytokine-induced, but not TCR-induced, IFN-gamma production. Nat Immunol 2001; 2:157-64; PMID:11175814; https://doi.org/10.1038/89769 10.1038/84264 10.1038/35052105
- O'Shea JJ, Lahesmaa R, Vahedi G, Laurence A, Kanno Y. Genomic views of STAT function in CD4+ T helper cell differentiation. Nat Rev Immunol 2011; 11:239-50; PMID:21436836; https://doi.org/10.1038/nri2958
- Ingram JT, Yi JS, Zajac AJ. Exhausted CD8 T cells downregulate the IL-18 receptor and become unresponsive to inflammatory cytokines and bacterial co-infections. PLoS Pathog 2011; 7:e1002273; PMID:21980291; https://doi.org/10.1371/journal.ppat.1002273
- Srivastava S, Salim N, Robertson MJ. Interleukin-18: biology and role in the immunotherapy of cancer. Curr Med Chem 2010; 17:3353-7; PMID:20712569; https://doi.org/10.2174/092986710793176348
- Tian H, Shi G, Yang G, Zhang J, Li Y, Du T, Wang J, Xu F, Cheng L, Zhang X et al. Cellular immunotherapy using irradiated lung cancer cell vaccine co-expressing GM-CSF and IL-18 can induce significant antitumor effects. BMC Cancer 2014; 14:48; PMID:24475975; https://doi.org/10.1186/1471-2407-14-48